BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 28781213)

  • 1. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
    Haider KS; Haider A; Doros G; Traish A
    J Urol; 2018 Jan; 199(1):257-265. PubMed ID: 28728990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone Therapy: What We Have Learned From Trials.
    Corona G; Torres LO; Maggi M
    J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement in men with sexual dysfunction.
    Lee H; Hwang EC; Oh CK; Lee S; Yu HS; Lim JS; Kim HW; Walsh T; Kim MH; Jung JH; Dahm P
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013071. PubMed ID: 38224135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).
    Maggi M; Wu FC; Jones TH; Jackson G; Behre HM; Hackett G; Martin-Morales A; Balercia G; Dobs AS; Arver ST; Maggio M; Cunningham GR; Isidori AM; Quinton R; Wheaton OA; Siami FS; Rosen RC;
    Int J Clin Pract; 2016 Oct; 70(10):843-852. PubMed ID: 27774779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L; Lazarou S; Morgentaler A
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
    Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
    Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy.
    Sumii K; Miyake H; Enatsu N; Matsushita K; Fujisawa M
    Andrologia; 2016 Mar; 48(2):198-202. PubMed ID: 25988884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of androgen receptor CAG polymorphism on sexual function recovery after testosterone therapy in late-onset hypogonadism.
    Tirabassi G; Corona G; Biagioli A; Buldreghini E; delli Muti N; Maggi M; Balercia G
    J Sex Med; 2015 Feb; 12(2):381-8. PubMed ID: 25443437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversial aspects of testosterone in the regulation of sexual function in late-onset hypogonadism.
    Maggi M; Filippi S; Vignozzi L; Rastrelli G
    Andrology; 2020 Nov; 8(6):1580-1589. PubMed ID: 32248652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
    Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive evaluation of androgen replacement therapy in aging Japanese men with late-onset hypogonadism.
    Okada K; Yamaguchi K; Chiba K; Miyake H; Fujisawa M
    Aging Male; 2014 Jun; 17(2):72-5. PubMed ID: 24533913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
    Yassin AA; Nettleship JE; Salman M; Almehmadi Y
    Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.